Equillium, Inc. (EQ) Stock

Equillium, Inc. (EQ) is a Healthcare stock trading at $2.29 (as of 2026-08-21), with a market capitalization of $145.20M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Equillium, Inc. is a clinical-stage biotechnology company developing and selling therapies for severe autoimmune, inflammatory, and immuno-inflammatory disorders with unmet medical need. Its pipeline includes itolizumab (EQ001) targeting CD6, with programs in acute graft-versus-host disease and other immune-related diseases, plus additional candidates such as EQ101 and EQ102.

Understand Equillium, Inc.: how it makes money

Equillium, Inc. is a clinical-stage biotechnology company that develops immuno-inflammatory disorder treatments, led by itolizumab (EQ001), and it generates revenue largely through itolizumab development funding and upfront payment amortization rather than established product sales.

Because Equillium is still in clinical development, its near-term profit model depends on external development funding and amortized upfront payments, while future product value is gated by clinical trial progress for EQ001 and the expansion of its pipeline.

Revenue by segment (latest quarter)
EQ001 Funding$0.0B
Upfront Amort.$0.0B

Business quality (Weak): The company’s fundamentals are driven by clinical development milestones for EQ001 and pipeline studies (including EQ101 and EQ102), while currently reported revenue is small and operating results are sharply negative, making execution risk and trial readouts the key swing factors.

Bull case

  • Late-stage path for lead asset: Itolizumab (EQ001) is in Phase III clinical trials for acute graft-versus-host disease, and the company has completed Phase Ib clinical trials for asthma and for lupus nephritis.
  • Defined biological target: EQ001 is a monoclonal antibody that targets CD6, described as a novel immune checkpoint receptor.

Bear case

  • Trial and outcome dependence: The company’s future commercial prospects rely on the success of clinical trials, including measured efficacy and safety outcomes, rather than on established product revenue.
  • Heavy losses and limited revenue visibility: Reported operating margin is deeply negative (operating_margin_pct is -1815.5), and the revenue segment mix shown is small, which can increase reliance on continued financing and partner support.
Valuation — source: SEC EDGAR (first-party)
Price$2.29
Market Cap$145.20M
Price / Book2.59
Price / Sales106.61
FCF Yield-25.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$833000.00
Net Margin-2688.8%
Revenue Growth (YoY)-98.0%
EPS Growth (YoY)69.6%
FCF Growth (YoY)19.3%
Financial Health — source: SEC EDGAR
Altman Z-Score15.55 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($20.69M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBruce D. Steel
Employees35
CountryUS
IPO Date2018-10-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • OnKure Therapeutics, Inc. (OKUR)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Assertio Holdings, Inc. (ASRT)
  • Unicycive Therapeutics, Inc. (UNCY)
  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Spruce Biosciences, Inc. (SPRB)
  • TuHURA Biosciences, Inc. (HURA)
  • Anixa Biosciences, Inc. (ANIX)
EQ earnings history · EQ institutional & insider holders · EQ KPIs & operating metrics · EQ financials · EQ investor presentations & press releases · EQ SEC filings · EQ peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.